In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
News|Podcasts|February 18, 2026
ACT Brief: AI Enables Real-Time Trial Oversight, Provider Engagement Strengthens Recruitment, and HHS Leadership Restructures Operations
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we examine how AI is enabling continuous trial monitoring and faster site decisions, how provider participation influences recruitment in pragmatic trials, and how leadership restructuring at HHS may shape health policy execution.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In Part 2 of a video
interview with ACT, Angela Zubel of Debiopharm said AI and digital tools are enabling real-time monitoring, faster site selection, and more efficient resource allocation across clinical trials. She noted that continuous data review can help sponsors identify non-performing sites sooner and redirect resources to improve enrollment efficiency. Zubel added that reducing delays tied to underperforming sites could significantly lower costs and accelerate timelines. - A new peer-reviewed
analysis of the Diuretic Comparison Project within the US Department of Veterans Affairs found that nearly 70% of invited primary care providers agreed to participate, supporting enrollment and randomization workflows. More than 13,500 patients were successfully randomized, representing 82% of those who consented to the study. The findings also showed that low-burden integration with routine care and clear provider communication helped sustain engagement throughout the trial. - Leadership
changes at the US Department of Health and Human Services have elevated CMS official Chris Klomp to oversee department operations while continuing his Medicare leadership roles. The restructuring is intended to strengthen coordination across agencies and support policy priorities, including drug pricing reforms and regulatory initiatives. Officials said the changes also reflect growing federal focus on healthcare affordability and operational oversight.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, about why defensible trial data depends on traceability, platform ownership, and device strategy long after a study ends.
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where
3
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
4
What ClinOps Professionals Just Starting With AI Should Keep Top of Mind
5